Mazor Robotics Ltd. (MZOR) Given “Hold” Rating at Needham & Company LLC
Mazor Robotics Ltd. (NASDAQ:MZOR)‘s stock had its “hold” rating reiterated by Needham & Company LLC in a note issued to investors on Wednesday.
Several other analysts also recently commented on MZOR. Zacks Investment Research raised shares of Mazor Robotics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 14th. Standpoint Research initiated coverage on shares of Mazor Robotics in a research report on Friday, July 8th. They issued a “buy” rating and a $30.00 price target for the company. Barclays PLC lifted their price target on shares of Mazor Robotics from $16.00 to $23.00 and gave the company an “overweight” rating in a research report on Thursday, July 14th. Finally, B. Riley initiated coverage on shares of Mazor Robotics in a research report on Thursday, October 6th. They issued a “neutral” rating and a $25.00 price target for the company. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $26.25.
Mazor Robotics (NASDAQ:MZOR) traded down 2.31% during mid-day trading on Wednesday, reaching $24.58. 146,946 shares of the company’s stock traded hands. The company has a 50 day moving average price of $23.33 and a 200-day moving average price of $18.19. Mazor Robotics has a 12 month low of $8.31 and a 12 month high of $26.55. The stock’s market cap is $532.72 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/mazor-robotics-ltd-mzor-given-hold-rating-at-needham-company-llc.html
Mazor Robotics (NASDAQ:MZOR) last announced its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. The company earned $8.30 million during the quarter, compared to the consensus estimate of $8.51 million. Mazor Robotics had a negative net margin of 60.75% and a negative return on equity of 42.30%. The company’s quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.05) EPS. On average, analysts anticipate that Mazor Robotics will post ($0.71) EPS for the current year.
A number of hedge funds have recently bought and sold shares of the stock. Oracle Investment Management Inc. increased its stake in Mazor Robotics by 13.0% in the fourth quarter. Oracle Investment Management Inc. now owns 2,816,635 shares of the company’s stock valued at $28,617,000 after buying an additional 323,724 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Mazor Robotics during the fourth quarter worth about $2,594,000. Iguana Healthcare Management LLC increased its position in Mazor Robotics by 60.0% in the second quarter. Iguana Healthcare Management LLC now owns 200,000 shares of the company’s stock worth $3,596,000 after buying an additional 75,000 shares in the last quarter. EAM Investors LLC purchased a new position in Mazor Robotics during the second quarter worth about $2,348,000. Finally, Candriam Luxembourg S.C.A. purchased a new position in Mazor Robotics during the second quarter worth about $1,079,000. 18.71% of the stock is owned by institutional investors and hedge funds.
About Mazor Robotics
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.